PMID- 23187789
OWN - NLM
STAT- MEDLINE
DCOM- 20130910
LR  - 20211021
IS  - 1432-2072 (Electronic)
IS  - 0033-3158 (Linking)
VI  - 226
IP  - 2
DP  - 2013 Mar
TI  - Influence of chronic caffeine on MDMA-induced behavioral and neuroinflammatory 
      response in mice.
PG  - 433-44
LID - 10.1007/s00213-012-2918-3 [doi]
AB  - RATIONALE: Previous research suggests that chronic daily caffeine administration 
      protects against brain injury in different animal models of neurodegenerative 
      diseases, such as Parkinson's and Alzheimer's diseases, ischemic and traumatic 
      brain injury, and allergic encephalitis. However, little is known about the 
      effects of chronic caffeine administration on 3,4-methylenedioxymethamphetamine 
      (MDMA)-induced neuroinflammation. OBJECTIVE: The present study examines whether 
      chronic caffeine (10, 20, or 30 mg/kg, i.p, for 21 consecutive days) protects 
      against MDMA-induced astrocytic and microglial activation in mice striatum, 
      impairing its neuroinflammatory effects. Additionally, locomotor activity, 
      sensoriomotor reflexes, body temperature, and anxiety were evaluated after 
      caffeine injection on days 0 (basal), 7, 14, and 21 of the chronic treatment in 
      order to assess possible behavioral alterations due to caffeine administration. 
      METHODS: On day 22, mice pretreated with caffeine or saline received a neurotoxic 
      regimen of MDMA (3 x 20 mg/kg, i.p., 2-h interval) or saline, and changes in body 
      temperature were evaluated. Forty-eight hours after last MDMA or saline injection 
      (day 24), the aforementioned behavioral parameters were investigated and 
      microglia and astroglia activation to MDMA treatment was examined in the mouse 
      striatum. RESULTS: Caffeine (10 mg/kg) chronically administered completely 
      prevented MDMA-induced glial activation without inducing physiological or 
      behavioral alterations in any of the assays performed. CONCLUSION: Chronic 
      caffeine consumption at low doses exerts anti-inflammatory effects and prevents 
      MDMA-induced neuroinflammation.
FAU - Ruiz-Medina, Jessica
AU  - Ruiz-Medina J
AD  - Grup de Recerca en Neurobiologia del Comportament-GReNeC, Departamento de 
      Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, C/Dr. Aiguader 
      88, 08003 Barcelona, Spain.
FAU - Pinto-Xavier, Ana
AU  - Pinto-Xavier A
FAU - Rodriguez-Arias, Marta
AU  - Rodriguez-Arias M
FAU - Minarro, Jose
AU  - Minarro J
FAU - Valverde, Olga
AU  - Valverde O
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121129
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Central Nervous System Stimulants)
RN  - 3G6A5W338E (Caffeine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Anxiety/chemically induced
MH  - Astrocytes/*drug effects/metabolism
MH  - Behavior, Animal/drug effects
MH  - Body Temperature/drug effects
MH  - Caffeine/*pharmacology
MH  - Central Nervous System Stimulants/*pharmacology
MH  - Corpus Striatum/drug effects/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Locomotion/drug effects
MH  - Male
MH  - Mice
MH  - Microglia/*drug effects/metabolism
MH  - N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage/*pharmacology
MH  - Neurotoxicity Syndromes/*prevention & control
MH  - Reflex/drug effects
MH  - Time Factors
EDAT- 2012/11/29 06:00
MHDA- 2013/09/11 06:00
CRDT- 2012/11/29 06:00
PHST- 2012/06/15 00:00 [received]
PHST- 2012/10/31 00:00 [accepted]
PHST- 2012/11/29 06:00 [entrez]
PHST- 2012/11/29 06:00 [pubmed]
PHST- 2013/09/11 06:00 [medline]
AID - 10.1007/s00213-012-2918-3 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2013 Mar;226(2):433-44. doi: 
      10.1007/s00213-012-2918-3. Epub 2012 Nov 29.